pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,106 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT801Endpoints604BioPharma Dive231onclive165Fierce Biotech74BioSpace70raps32fda recalls20globenewswire health
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Which vaccines will curb the Ebola outbreak? WHO debates
    The growing Ebola outbreak, the unknowns of microdosing GLP-1s, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    STAT · 2mo ago↗ source
  • Pfizer, Innovent strike $10B cancer drug deal
    Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.
    BioPharma Dive · 2mo ago↗ source
← prev
page 30 of 45
next →
20
fda press20
fda medwatch16
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • STAT+: The woman behind the world’s biggest longevity competition
    Jamie Justice of XPRIZE Healthspan on the most promising research and "purely scammy" treatments in the world of longevity.
    STAT · 2mo ago↗ source
  • Opinion: I’m a weight-loss doctor. Here’s why I worry about GLP-1 ‘microdoses’
    Long term, we don’t know what tiny doses of GLP-1s for cosmetic weight loss can do, writes a weight-loss doctor.
    STAT · 2mo ago↗ source
  • STAT+: As Ebola outbreak in Central Africa grows, the U.S. turns itself into a fortress
    The U.S. is taking extraordinary steps to keep Ebola out. But its policies may create risks for Americans infected overseas and discourage volunteers from responding to the outbreak.
    STAT · 2mo ago↗ source
  • GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’
    The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.
    BioPharma Dive · 2mo ago↗ source
  • CVS obesity drug deal puts Lilly on equal footing with Novo
    The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: 23andMe offers to connect users’ DNA data with medical records
    23andMe is partnering with HealthEx to allow users to import their medical records, the company said Tuesday at STAT Breakthrough Summit West.
    STAT · 2mo ago↗ source
  • STAT+: Marc Tessier-Lavigne addresses new book’s allegations about his conduct in Stanford misconduct case
    Former Stanford President Marc Tessier-Lavigne responded publicly for the first time, at a STAT event Tuesday, to allegations in a new book about why he was forced to resign.
    STAT · 2mo ago↗ source
  • Trump’s cuts to foreign aid are undermining the Ebola response, insiders say
    President Trump's cuts to foreign aid probably hampered the detection of the Ebola outbreak and the response to it.
    STAT · 2mo ago↗ source
  • STAT+: Virginia governor vetoes legislation to create an advisory panel to lower the cost of prescription drugs
    Virginia's governor vetoed a closely watched effort to create an advisory panel to lower prescription drug costs.
    STAT · 2mo ago↗ source
  • STAT+: This spine surgery usually costs $1,400. Under No Surprises Act arbitration? $34,000
    A new analysis shows how some clinicians are cashing in on a new process designed to protect patients from surprise bills.
    STAT · 2mo ago↗ source
  • How AI helped treat a newborn’s ultra rare disease. ‘It was almost like a light switch.’
    The parents of Jorie Kraus told the audience at STAT's Breakthrough Summit West about how AI helped their daughter who was born with a rare disease.
    STAT · 2mo ago↗ source
  • STAT+: Canadian medical societies lack sufficient conflict-of-interest policies, study finds
    Most Canadian medical societies lack comprehensive policies governing conflicts of interest, and many policies are generally fragmented and narrow in scope, according to a new analysis.
    STAT · 2mo ago↗ source
  • STAT+: At a time of tumult at FDA, a former commissioner is hopeful it’s on a better path
    With the FDA facing upheaval and personnel exits, former commissioner David Kessler sees an opportunity whereby the agency can make a turn for the better.
    STAT · 2mo ago↗ source
  • STAT+: TrumpRx adds generic drugs
    A deal with Mark Cuban, Amazon Pharmacy, and GoodRx is boosting TrumpRx's offerings.
    STAT · 2mo ago↗ source
  • BioMarin drug acquired in buyout misses goal in rare disease study
    Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects.
    BioPharma Dive · 2mo ago↗ source
  • A migraine drugmaker heads to the public markets through reverse merger
    Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: Dexcom CEO hints at future uses for CGM
    In this edition of STAT Health Tech: Takeaways from a conversation with Dexcom CEO, and updates on WiSeR, and Epic's market share.
    STAT · 2mo ago↗ source
  • STAT+: A new ranking of pharma companies by R&D performance
    Maryland drug board to cap price of Ozempic, TrumpRx partners with Cuban, GoodRx, and more biotech news
    STAT · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much more
    The latest pharmaceutical news from the Pharmalot campus via the Pharmalittle newsletter
    STAT · 2mo ago↗ source
  • Relay drug shows early promise against rare blood vessel diseases
    While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: Eli Lilly tops prominent rankings on pharma R&D performance
    A new set of lists ranks drug company laboratories on two criteria: innovation and invention.
    STAT · 2mo ago↗ source
  • The latest on Ebola: A travel ban and an old vaccine
    Affordable Care Act changes, drinking while pregnant, and more health news from Morning Rounds
    STAT · 2mo ago↗ source